Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net Revenue	$ 15,521,917	$ 7,811,223
Cost of goods sold	2,125,659	805,081
Gross profit	13,396,258	7,006,142
Operating expenses
Selling, general and administrative expenses	12,969,069	9,375,630
Research and development	1,317,324	204,637
Depreciation and amortization	778,875	202,747
Change in fair value of earnout liabilities	(452,687)
Total operating expenses	14,612,581	9,783,014
Operating loss	(1,216,323)	(2,776,872)
Other expense
Interest expense	(6)
Share of losses from equity method investment		(379,633)
Total other expense	(6)	(379,633)
Net loss	(1,216,329)	(3,156,505)
Less: Net loss attributable to noncontrolling interest	(38,429)	(27,181)
Net loss attributable to Sanara MedTech shareholders	$ (1,177,900)	$ (3,129,324)
Net loss per share of common stock, basic and diluted	$ (0.14)	$ (0.41)
Weighted average number of common shares outstanding, basic and diluted	8,173,784	7,606,450